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Abstract
Modulation of endogenous cellular defense mechanisms via the vitagene system represents an innovative approach to
therapeutic intervention in diseases causing chronic tissue damage, such as in neurodegeneration. The possibility of
high-throughoutput screening using proteomic techniques, particularly redox proteomics, provide more comprehensive
overview of the interaction of proteins, as well as the interplay among processes involved in neuroprotection. Here by
introducing the hormetic dose response concept, the mechanistic foundations and applications to the field of
neuroprotection, we discuss the emerging role of heat shock protein as prominent member of vitagene network in
neuroprotection and redox proteomics as a tool for investigating redox modulation of stress responsive vitagenes.
Hormetic mechanisms are reviewed as possibility of targeted therapeutic manipulation in a cell-, tissue- and/or
pathway-specific manner at appropriate points in the neurodegenerative disease process.
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Cellular stress response and the vitagene system
Protein thiols play a key role in redox sensing, and regu-
lation of cellular redox state is a crucial mediator of
multiple metabolic, signalling and transcriptional pro-
cesses [1]. Under optimal conditions long-term health is
maintained by protein homeostasis, a highly complex
network of molecular interactions that balances protein
biosynthesis, folding, translocation, assembly/disassem-
bly, and clearance [2, 3]. Protein quality control is a crit-
ical feature of intracellular homeostasis [4]. When
conformationally challenged aggregation-prone proteins
are expressed, the resulting unfolded or misfolded pro-
teins are rapidly degraded via the ubiquitin–proteasome
pathway. The ability of a cell to counteract stressful con-
ditions is also known as cellular stress response or heat
shock response, which is an ancient and highly
conserved cytoprotective mechanism [3, 5]. Production
of heat shock proteins (HSP), including protein chaper-
ones, is essential for the folding and repair of damaged
proteins, serving thus to promote cell survival condi-
tions that would otherwise result in apoptosis [6]. There
is significant interest in the discovery and development
of small molecules that modulate heat shock responses
and parallel stress response pathways for therapeutic
purposes [1, 7–9]. The cellular stress response is regu-
lated at the transcriptional, translational and post-
translational levels. The major regulator of the heat
shock response genes is the heat shock transcription fac-
tor 1 (HSF1) which is kept in a latent state by an inhibi-
tory complex of stress-proteins, and plays a key
regulatory role in response to environmental stress,
development, and many pathophysiological conditions,
including cancer, ischemia-reperfusion injury, diabetes,
and aging [10, 11] (Fig. 1).
Mammalian cells contain at least 3 HSF family mem-
bers, HSF1, HSF2 and HSF4 [12, 13]. Neurons appear to
be deficient in the heat shock response while retaining
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the ability to express such HSF proteins [14]. Further-
more, HSF1 fails to be activated in motor neurons even
when these cells are microinjected with plasmids encod-
ing an HSF1 expression vector, suggesting a block to the
HSF1 signal transduction pathways [15]. HSF1 is
repressed under non-stress conditions by a complex
containing Hsp90 and other proteins. In this inactive
state, HSF1 is a monomer that lacks the ability to bind
cis -acting heat shock elements (HSE) in the promoters
of HSP genes. Protein stress results in conversion of
HSF1 from inactive monomer to DNA binding trimer
and remodeling of the inhibitory molecular chaperone
complex [16]. Activation of HSF1 by heat shock is a
multi-step process, involving multiple inducible phos-
phorylation, dephosphorylation, acetylation and deacety-
lation steps, the sum of which results in the
transcription of HSP genes. Extracellular signal input
during heat shock involves tyrosine phosphorylation up-
stream of HSF1, involves the receptor tyrosine kinase
HER2 and launches downstream signaling cascades
through intracellular kinase Akt [17]. Akt regulates
HSF1 at least in part by modulating its association with
the phosphoserine binding scaffold protein [17].
The major activator of HSF1 is proteotoxic insults, like
heat shock. Misfolded proteins displace HSF1 form the
inhibitory chaperone complex, HSF1 trimerizes,
Fig. 1 Vitagenes and the pathway of cellular stress response. Proteotoxic stresses causing accumulation of misfolded proteins trigger the cellular
stress response. HSPs that are normally bound to HSF1 are titrate away by damaged proteins with resulting HSF-1 activation. Multi-step activation
of HSF1 involves post-translational modifications, such as hyperphosphorylation, deacetylation or sumoylation, which allow HSF1 to trimerize,
translocate into the nucleus, and bind to heat-shock elements (HSEs) in the promoter regions of its target hsp genes. Nutritional antioxidants, are
able to activate vitagenes, such as heme oxygenase, Hsp70, thioredoxin reductase and sirtuins which represent an integrated system for cellular
stress tolerance. Activation of Vitagene system, with up-regulation of HO-1, Thioredoxin, GSH and Sirtuin, results in reduction of pro-oxidant
conditions. During inflammaging, including aged-associated pathologies a gradual decline in potency of the heat shock response occur and this
may prevent repair of protein damage, leading to degeneration and cell death of critical parenchymal cells. Phytochemicals and acetylcarnitine
act through the activation of transcription factor Nrf2, which after binding to the antioxidant responsive element up-regulates vitagenes
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becomes phosphorylated and is translocated to the nu-
cleus where it is able to bind to the heat shock element
of HSP genes [18, 19].
Cellular stress response requires the activation of
pro-survival pathways as well as production of mole-
cules endowed with anti-oxidant and anti-apoptotic
activities, which is under control of protective genes
called vitagenes [1, 4, 7]. Generally, molecular chaper-
ones help hundreds of signaling molecules to keep
their activation-competent state, and regulate various
signaling processes ranging from signaling at the
plasma membrane to transcription. In addition to
these specific regulatory roles, recent studies have re-
vealed that chaperones act as genetic buffers stabiliz-
ing the phenotypes of various cells and organisms
[19]. This may be related to their low affinity for the
proteins they interact with, which means that they
represent weak links in protein networks [20]. Chap-
erones may uncouple protein, membrane, organelle
and transcriptional networks during stress, which
gives the cell additional protection. The same net-
works are preferentially remodeled in various diseases
and aging, which may help us to design novel thera-
peutic and anti-aging strategies [21]. Among the
cellular pathways involved in the so called “pro-
grammed cell life” and conferring protection against
oxidative stress, a key role is played by the products
of vitagenes [1, 4, 7, 22–25]. These include members
of the HSP family, such as heme oxygenase-1 (HO-1),
Hsp72, sirtuins and thioredoxin/thioredoxin reductase
(Fig. 1) [7, 26, 27]. Heme oxygenase-1, also referred
to as Hsp32, degrades heme, which is toxic if
produced in excess, into free iron, carbon monoxide
and biliverdin (BV) this latter being the precursor of
bilirubin, a linear tetrapyrrole which has been shown
to effectively counteract oxidative and nitrosative
stress due to its ability to interact with NO and RNS
[28, 29]. Sirtuins are a group of proteins linked to
aging, metabolism and stress tolerance in several or-
ganisms [30, 31]. Mammalian sirtuins are histone dea-
cetylases, requiring NAD+ as a cofactor to deacetylate
substrates ranging from histones to transcriptional
regulators. Through this activity, sirtuins are shown
to regulate important biological processes, such as
apoptosis, cell differentiation, energy transduction and
glucose homeostasis [30]. Recent studies have shown
that the heat shock response contributes to establish-
ing a cytoprotective state in a wide variety of human
diseases, including inflammation, cancer, aging and
neurodegenerative disorders. Given the broad cytopro-
tective properties of the heat shock response there is
now strong interest in discovering and developing
pharmacological agents capable of inducing the heat
shock response [1].
Heat shock proteins and neuroprotection
In response to various forms of stress, cells activate a
highly conserved heat shock response in which a set of
HSP are induced, which play important roles in cellular
repair and protective mechanisms [3, 32]. Evidence sug-
gests that manipulation of the cellular stress response may
offer strategies to protect brain cells from damage that is
encountered following cerebral ischemia or during the
progression of neurodegenerative diseases [1, 27, 33, 34].
Heat shock proteins are evolutionarily conserved and
present in all cellular compartments. Some of the major
chaperones (Hsp70, Hsp90, small Hsps) are present at
high concentrations in non-stressed cells reaching 1–5 %
of total cellular protein, consistent with an important role
for chaperones in cellular homeostasis. Indeed, chaper-
ones display various activities in the cell, such as (i) proper
folding of nascent polypeptide chains, (ii) facilitating pro-
tein translocation across various cellular compartments,
(iii) modulating protein activity through stabilization and/
or maturation to functionally-competent conformation,
masking mild mutation at the conformational level
(iv) promoting multiprotein complex assembly/disas-
sembly, (v) refolding of misfolded proteins, (vi)
protecting against protein aggregation, (vii) targeting
irreversibly damaged proteins to degradation, (viii) se-
questering damaged proteins [35, 36].
Heat shock proteins are classified according to their
molecular weight [37]. The 70 kDa family of stress pro-
teins is one of the most extensively studied. Included in
this family are HSC70 (heat shock cognate, the constitu-
tive form), HSP70 (the inducible form, also referred to
as HSP72) and GRP-75 (a constitutively expressed
glucose-regulated protein found in the endoplasmic
reticulum) [5]. Heat shock proteins 70 function in co-
and post-translational folding and the quality control of
misfolded proteins [38]. More specifically, HSP70 par-
ticipate in folding and assembly of newly synthesized
proteins into macromolecular complexes; aggregation
prevention; dissolution and refolding of aggregated pro-
teins; as well as protein degradation [20]. Heat shock
proteins 70 have an N-terminal ATP-binding domain
(NBD) and a C-terminal substrate-binding domain
(SBD) which are both critical for chaperone function.
Non-native substrates with exposed hydrophobic
stretches within an accessible polypeptide backbone as-
sociate transiently with HSP70 via its SBD. ATP binding
to the NBD triggers opening of the SBD binding pocket,
decreasing affinity for polypeptide substrates, thereby ac-
celerating both on and off rates. Reciprocally, substrate
binding induces ATP hydrolysis, ‘closing’ the SBD and
thus stabilizing the substrate-HSP70 complex [20]. It is
this cycle of rapid but controlled binding and release of
the substrate that fosters folding and assembly with part-
ner proteins while preventing aggregation of substrates;
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however, detailed mechanistic understanding of how
HSP70 accomplishes these feats is not yet available [20].
Numerous hypotheses have been put forth to explain
the molecular mechanism of HSP70-induced structural
conversion of substrate proteins. For example, an ‘en-
tropic pulling’ mechanism has been proposed, whereby
HSP70 binding stabilizes peptide segments in an un-
folded state, causing local unfolding, thereby facilitating
disaggregation and allowing refolding upon HSP70 re-
lease [39]. Co-factors, such as the nucleotide exchange
factors (NEFs) and co-chaperones, are crucial regulatory
components of the HSP70 cycle that confer versatility
and specificity to the HSP70 chaperone machine [20].
The HSP40 co-chaperone targets substrates to HSP70
while stimulating ATP hydrolysis; NEFs like Bag-1
(BCL2- associated athanogene 1) and HSP110 reinitiate
the HSP70 cycle by facilitating ADP release and rebind-
ing of ATP [40]. Moreover, Bag-1 has the additional
ability to bind to the 26S proteasome and another BAG
isoform, the Bag-3 co-chaperone, links HSP70 to the
macroautophagic degradation pathway during aging
[17]. CHIP (carboxy terminus of HSC70-interacting
protein), a co-chaperone of HSP70 that also has E3 ubi-
quitin ligase activity, cooperates with Bag-1, and possibly
Bag-3, in order to facilitate degradation of terminally
misfolded substrate proteins. Notably, mutations in
HSP70 co-factors are lethal [41] or may be associated
with neurodegenerative disease [41, 42].
Recent studies indicate that the heat shock response
declines in aging cells and becomes weaker as organisms
live beyond the mature adult stage [17]. Cells lose the
capacity to activate the transcriptional pathways leading
to HSP synthesis (Fig. 1). In neuronal tissues, decline in
protein quality control has been widely predicted, as the
etiology of a number of diseases involve aggregation-
prone proteins that form inclusion bodies whose occur-
rence is linked to pathology. Heat shock protein 70 has
been extensively implicated in the pathogenesis of
misfolding disease [17]. Numerous studies indicate that
HSP70 and components of the ubiquitin–proteasome
system associate with inclusion bodies/plaques charac-
teristic of misfolding diseases, indicating a general
activation of the cellular quality control machinery in an
attempt to circumvent the accumulation of misfolded
species [43]. In these conditions the HSP70 system is
unable to refold disease-related proteins, causing per-
turbation of protein homeostasis associated with disease
onset. Several hypotheses account for this apparent
disruption of the balance between the production of
misfolded proteins and HSP70 activity. As misfolded dis-
ease proteins accumulate, these can overwhelm the cap-
acity of the HSP70 system to control the cellular folding
milieu [32]. Progressive reduction in protein levels and/
or activity of HSP70 and other components of the
quality control network may exacerbate this imbalance,
permitting further accumulation of toxic misfolded pro-
teins. Such reduction could be due to the ageing process,
as transcription of HSP70 decreases during ageing of the
human brain. Alternatively, disease processes themselves
might cause, or worsen, chaperone deficiency. Inclusions
have been proposed to sequester HSP70 and other pro-
teins in a non-functional state, inhibiting their essential
function in cellular processes [20].
Another studies about diabetes DPN is unrelated to
one specific misfolded protein aggregate, In this case
hyperglycemia can promote the oxidative modification
of amino acids [44] that may impair protein folding [45],
decrease mithochondrial protein import [46], and pro-
mote mitochondrial dysfunction [47].
The availability of transgenic animals and gene transfer
allowing over-expression of the gene encoding for
HSP70, has revealed that overproduction of this protein
leads to protection in several different models of nervous
system pathology [4]. Overexpression of HSP70 and/or
its co-chaperones suppresses aggregation and toxicity in
models of misfolding disease [48]. Increased HSP70
levels caused reduced aggregation and toxicity of tau
and Aβ, respectively, two components associated with
Alzheimer’s disease [5]. Similarly, overexpression of
HSP70 reduces toxicity and accumulation of α-synuclein
in high molecular weight and detergent-insoluble de-
posits [5]. Increased expression of HSP70 has been re-
ported to be associated with a decrease in apoptotic cell
death, an increase in the expression of the antiapoptotic
protein Bcl-2, a suppression of microglial/monocyte acti-
vation, and a reduction in matrix metalloproteinases.
Up-regulation of HSP70 likewise reduced apoptosis and
the formation of co-aggregates of the prion disease pro-
tein, PrP [4]. Numerous studies have also shown that
HSP70 overexpression reduces polyQ toxicity. Results
obtained in vitro have elucidated the mechanism of ac-
tion of HSP70 against misfolding and thus toxicity of
disease proteins. Purified HSP70 acts preferentially on
monomers or oligomers, rather than fibrillar aggregates
of Aβ, huntingtin, and α-synuclein species modulating
the aggregation process [4]. Heat shock proteins 70 in-
hibits the aggregation of Aβ and α-synuclein species
even at substoichiometric levels, suggesting that HSP70
can recognize multimeric protein assemblies [20]. As
mentioned before, the effect of HSP70 on aggregation,
which requires its ATPase activity, is enhanced by the
cochaperone HSP40. Thus, HSP70 together with HSP40
stabilizes huntingtin in a monomeric conformation and
prevents accumulation of spherical oligomers which are
the toxic species for fibril formation [49]. As a result,
mutant huntingtin is deviated from the potentially toxic,
fibrillar aggregation pathway and instead accumulates in
amorphous aggregates, or other benign conformers.
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Sequestered in these conformers, mutant huntingtin
may no longer participate in heterotypic interactions
known to inactivate essential cellular machinery, such as
polyQ-containing transcription factors [49, 50].
Following focal cerebral ischemia, HSP70 mRNA is
synthesized in most ischemic cells except in areas of
very low blood flow, due to scarce ATP levels. Heat
shock proteins 70 are produced mainly in endothelial
cells, in the core of infarcts in the cells that are most re-
sistant to ischemia, in glial cells at the edges of infarcts
and in neurons outside the areas of infarction [51]. It
has been suggested that this neuronal expression of
HSP70 outside an infarct can be used to define the is-
chemic penumbras, which means the zone of protein de-
naturation in the ischemic areas, consistently in in vivo
transgenic mice overexpressing HSP70, compared to
wild-type mice in a middle cerebral artery occlusion
model of permanent cerebral ischaemia, it has been
demonstrated that overexpression of HSP70 reduces the
overall lesion size and also limits the tissue damage
within the lesion [51]. Heat shock protein 70 overexpres-
sion in post-mortem cortical tissue of AD patients and
an increase in HSP70 mRNA were found in cerebellum
hippocampus and cortex of AD patients during the ago-
nal phase of the disease [4, 37]. Consistently, the use of
agents that limit microglial activation and inflammation
in AD has recently emerged as an attractive therapeutic
strategy for this disease. For instance, the vasoactive
intestinal peptide (VIP), has been shown to prevent
Abeta-induced neurodegeneration, through inhibition
of major pathways involved in the production of in-
flammatory mediators, such as the p38 MAPK, p42/
p44 MAPK, and NFkB cascades, in activated micro-
glial cells [52]. In keeping with this, HSP70 induces
IL-6 and TNFα in microglial cells in a mechanism
which has been demonstrated to be NFkB and p-38
MAPK-dependent [53] and this leads to an increased
phagocytosis and clearance of Aβ.
A large body of evidence now suggests a correlation
between mechanisms of nitrosative stress and HSP in-
duction. We have demonstrated in vitro and in vivo
that cytokine-induced nitrosative stress is associated
with an increased brain synthesis of HSP70 stress
proteins. The molecular mechanisms regulating the
NO-induced activation of heat-shock signal seems to
involve cellular oxidant/antioxidant balance, mainly
represented by the glutathione status and the antioxi-
dant enzymes [1, 54, 55].
Neuroprotective effects of extracellular heat shock proteins
Heat shock proteins are transferred between cell types in
the nervous system. Thus, stress tolerance in neurons is
not solely dependent on their own HSP, but can be sup-
plemented by additional HSP transferred from adjacent
glial cells. Therefore, supplying exogenous HSP at neural
injury sites could be an effective strategy to maintain
neuronal viability. This idea has been tested in a number
of model systems. Injection of HSC/HSP70 into the vit-
reous chamber of the eye protected retinal photorecep-
tors from photodamage. Application of exogenous HSC/
HSP70 to the cut end of the sciatic nerve reduced cell
death in sensory and motor neurons. Extracellular
HSP70 protected spinal cord motor neurons deprived of
trophic support in vitro or undergoing cell death in vivo.
Thus, exogenous application of HSP has potential as a
therapeutic strategy for acute injury in the nervous sys-
tem. Heat shock proteins are released into the blood
stream after stressful stimuli and this may represent an
important feature of the stress response. Exercise stress
has been reported to induce the release of HSP70 from
the human brain into the blood stream in vivo. The bio-
logical significance of this neural release is yet to be de-
termined [56, 57]. In addition, stress proteins, such as
HSP90 are necessary for the maturation of several
transcription factors, including the nuclear hormone
receptors and the hypoxia-inducible factor-1 [58]. Re-
markably, there is increasing interest in the interaction
between Hsp90 and p53 [59], the latter being a tran-
scription factor regulating apoptosis, cell cycle arrest,
senescence, DNA repair and genetic stability, and is acti-
vated primarily during cellular responses to DNA dam-
age [60]. Consistently, a large number of proteins need
the help of molecular chaperones to maintain their
activation-competent conformation. ‘Conventional’ in-
hibitors interact with their target, directly inhibiting its
function. However, chaperone-based inhibitors do not
interact with the effector proteins, but inhibit the ability
of the associated chaperone(s) to maintain their
activation-competent conformation. As a result, the cli-
ent proteins became degraded by the proteasome [38].
Due to its biological relevance in the folding, maturation
and stabilization of pro-tumorigenic client proteins,
HSP90 is emerging as therapeutic target in cancer treat-
ment, representing a viable drug target for the design of
chemotherapies [38].
The heme oxygenase family
The heme oxygenase (HO) isoforms have been recog-
nized as dynamic sensors of cellular oxidative stress and
modulators of redox homeostasis throughout the phylo-
genetic spectrum. Two main isoforms of heme oxygen-
ase were identified so far and named HO-1 and HO-2
[61, 62]. Heme oxygenase-1 is the inducible isoform and
it is overexpressed under conditions of oxidative/nitrosa-
tive stress whereas heme oxygenase-2 is the constitutive
enzyme and it plays a main role in the physiologic turn-
over of cellular heme [61, 62]. Interestingly, although the
constitutive nature, HO-2 (no HO-1!!!!) is also up-
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regulated as an effect of some drugs, such as glucocorti-
coids, opiates and nitric oxide [61–63]. Though this dif-
ferent behavior in terms of regulation, both HO-1
and HO-2 catalyze the same reaction, namely the oxi-
dation of the alpha-meso-carbon bridge of the heme
moieties of hemoproteins thus generating equimolar
amounts of ferrous iron, carbon monoxide (CO) and
biliverdin (BV) [62, 64].
Among these by-products of HO activity (Fig. 2), CO
is mainly involved in the regulation of important func-
tions such as neurotransmission, regulation of neuropep-
tide release and modulation of the local/systemic
immune-inflammatory response [65–68]. As far as BV
concerns, it is a “virtual” by-product in mammal cells,
because it is rapidly reduced to bilirubin (BR) by the
cytosolic biliverdin reductase (BVR) [62]. Worth of not-
ing is the fact that HO and BVR have to be considered
as a single “fighter” against free radicals because of they
reach the maximum of the antioxidant power when they
act in concert. Over the last years, the role of BVR in
the adaptive stress response was under-estimated be-
cause this enzyme was only considered necessary for the
production of BR, which is responsible for free radical
scavenging (Fig. 2). Several lines of evidence underlined
the role of the HO/BVR system in the central nervous
system and in neurodegenerative diseases. Previous pre-
clinical studies put forth the idea of the neuroprotective
role of the HO/BVR system because of its ability to (i)
restore redox imbalance [2, 69], (ii) interact with neuro-
trophins [70], (iii) nitric oxide [71] and (iv) trap both re-
active oxygen and nitrogen species [72–75]. However,
recent results obtained in post-mortem brain tissues of
subjects with Alzheimer’s disease (AD) demonstrated a
down-regulation of both HO-1 and BVR in cognitive the
hippocampus, a brain area involved in cognitive
function. The down-regulation of these enzyme was sec-
ondary to phosphorylative, oxidative and/or nitrosative
post-translational modification on the protein structures
[75, 76]. These post-translational modifications are re-
sponsible for a reduced production of bilirubin and im-
paired interaction of BVR with members of the MAPK
family [75]. A first corollary of these results is that the
HO-1/BVR axis is not able to fully protect hippocampus
in AD individuals. A possible approach to overcome this
limitation in the neuroprotective activity is to prevent
the oxidative and nitrosative modifications occurring on
both HO-1 and BVR thus restoring their antioxidant po-
tential. Very recently, atorvastatin, a well known hypo-
lipidemic drug was shown to reduce oxidative/
nitrosative stress biomarkers in the parietal cortex of
aged canine, which is currently considered as the best
predictive preclinical model to study dementia of
Alzheimer type [77]. In particular, atorvastatin (80 mg/
day for 14.5 months) was able to prevent oxidative/
nitrosative modification on both HO-1 and BVR in the
parietal cortex of aged canine [78, 79]. Importantly, ator-
vastatin increased BR production in the parietal cortex
and improved cognitive skills in aged beagle dogs [79].
Taken together, these results demonstrate that the HO-
1/BVR axis can be modulated by atorvastatin and open
new avenues in terms of activation of the HO-1/BVR
system and neuroprotection [80, 81].
Fig. 2 Heme metabolism and HO-1 enzyme activity. HO-1 catalyze the rate-limiting step in heme metabolism. Heme is cleaved by HO-1 to yield
equimolar quantities of iron, CO, and biliverdin. The regulatory actions of CO can be, at least in part mediated, by the activation of MAPK pathway.
Biliverdin is converted to bilirubin by biliverdin reductase, this latter being also endowed with Ser/Thr/Tyr kinase activity through which regulates
cell growth and metabolism. At low physiological concentrations, bilirubin behaves as a powerful antioxidant
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Hormesis
Hormesis is the most powerful endogenous protective
mechanism against life threatening ischemic and oxida-
tive insults to multiple organ systems [82]. It is a dose
response phenomenon characterized by a low dose
stimulation and a high dose inhibition (Fig. 3), that may
be graphically represented by either an inverted U-
shaped dose response or by a J- or U-shaped dose
response. The term hormesis was first presented in the
published literature in 1943 by Southam and Ehrlich
who reported that low doses of extracts from the Red
Cider tree enhanced the proliferation of fungi with the
overall shape of the dose response being biphasic. How-
ever, credit for experimentally demonstrating the occur-
rence of hormesis goes to Hugo Schulz [83] who
reported biphasic dose responses in yeast following
exposure to a large number of toxic agents. The work of
Schulz inspired a large number of investigators in di-
verse fields to assess whether such low dose effects may
be a general feature of biological systems. In fact, similar
types of dose response observations were subsequently
reported by numerous researchers assessing chemicals
[84] and [85–93] with investigators adopting different
names such as the Arndt-Schulz Law, Huppe’s Rule, and
other terms to describe these similar dose response
phenomena.
Hormesis concept had a difficult time being incorpo-
rated into routine safety assessment and pharmaco-
logical investigations, principally because it (i) required
more rigorous evaluation in the low dose zone, (ii) fail-
ure of investigators to understand its clinical significance
(iii) failure to appreciate the quantitative features of the
hormetic dose response (iv) failure to understand the
limitations of its implications for commercial applica-
tions in agricultural as well as medicine, (v) because of
the predominant interest in responses at relatively high
doses during most of the 20th century as well as (vi) the
continuing, yet inappropriate, tendency to associate the
concept of hormesis with the medical practice of hom-
eopathy [94–97]. However, from the late 1970’s [98]
there has been a growing interest in hormetic-like bi-
phasic dose responses across the broad spectrum of bio-
medical sciences. This resurgence of interest resulted
from a variety of factors, including the capacity to meas-
ure progressively lower doses of drugs and chemicals
and the adoption of cell culture methods which has per-
mitted more efficient testing. Re-examine the validity of
linear at low dose modelling of cancer risks due to their
enormous cost implications for regulations [99, 100] as
well the astute observations of independent investigators
and their capacity to generalize their findings across bio-
logical systems [98, 101].
What has emerged from these research initiatives from
highly diverse biomedical areas is the recognition that
hormetic dose responses were common and highly
generalizable, being independent of biological model,
endpoints measured and chemical class and/or physical
agent studied [84, 85, 92, 102, 103]. This was an unex-
pected finding as hormetic responses were often consid-
ered by many in the so-called mainstream branches of
toxicology and pharmacology to be paradoxical, not
commonly expected and being of questionable reliability
Fig. 3 Dose–response curve depicting the quantitative features of hormesis
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with a lack of capacity for replication. The casual dismis-
sal of the hormesis concept during the mid decades of
the last century is reflected in the general absence of the
hormesis concept from the leading toxicological and bio-
medical textbooks. This situation has radically changed
such that hormesis is now incorporated into all leading
textbooks of toxicology [104] encyclopedias [105–107]
and other leading monographs. In fact, while the terms
hormetic and hormesis were cited only about 160 times
during the entire decade of the 1980’s within the Web of
Science database, in 2014 alone these terms were cited
over 6,000 times.
Of further significance were observations that these
broad ranging dose response relationships also shared
the same general quantitative features. More specifically,
the low dose stimulation which becomes manifested im-
mediately below the pharmacological and toxicological
thresholds is modest in magnitude being at most only
about 30–60 % greater than the control group response.
The width of the hormetic stimulation is usually about
10–20 fold starting immediately from the zero equiva-
lent dose (i.e., estimated threshold) (Fig. 3). The hor-
metic dose response may result from either a direct
stimulation or via an overcompensation stimulatory re-
sponse following disruption in homeostasis [107, 108].
Regardless of the mode of action by which the stimula-
tion occurs the quantitative features of hormetic dose
responses are similar. These observations are based
on copious data derived from the published literature
ranging from plants to humans [109, 110], involving
numerous receptor systems [111, 112]. These findings
have led to nearly 60 biomedical scientists recom-
mending that biological stress responses, including
those of pre- and post-conditioning, be integrated
within an hormetic context, along with the adoption
of a terminology that would be based within an inter-
disciplinary framework [113].
The hormetic dose response confers a new set of inter-
pretations for the dose response. At high doses within a
toxicological setting, the typical endpoints measured indi-
cate cellular damage. However, as the dose decreases
below the threshold the low dose stimulation more likely
represents a manifestation of an adaptive response that
conforms to a measure of biological performance as may
be seen in the cases of modest increases in cognition,
growth, longevity, bone density and other biomedical end-
points of interest. The consistency of the vast array of hor-
metic findings suggests strongly that this dose response
may be a manifestation of the plasticity of biological
systems. Numerous papers have explored how horm-
esis may affect aging and numerous diseases associ-
ated with age including cardiovascular disease and a
range of neurodegenerative conditions and their
underlying mechanisms [114–118]. How the hormesis
concept may prolong life and reduce the occurrence
of chronic disease involves the optimized challenging
of cells and whole organisms by any of a wide range
of stressors including pharmacological, physical, diet-
ary, exercise, and ischemic. Using a wide variety of in
vitro and in vivo models, anti-aging and neuroprotec-
tive effects have been reported using hormetic experi-
mental protocols [119–122]. Essentially all biological
models respond to imposed stress with the same
quantitative features of the dose response is a central
finding within the biological sciences that has not
been previously recognized. These findings suggest
that the hormetic dose response would have been
broadly selected for and highly conserved. This adaptive
response not only enhances survival by conferring resist-
ance to environmental stress but it represents a way to
regulate the allocation of biological resources in a manner
that ensures cellular and organismal stability.
These quantitative features of the hormetic dose re-
sponse have important medical implications. Most signifi-
cantly, the hormetic dose response imposes constraints
upon the magnitude of a drug to induce a desired effect.
For example, if a drug increased cognitive performance in
an elderly patient by approximately 25–30 %, the hormetic
model suggests that this level of performance could not be
further increased using a new drug combination. This
concept has been supported in a variety of studies on
hormesis and drug interaction. Flood [123, 124] has dem-
onstrated that the hormetic response for memory was
bounded by the 30–60 % increase even when several drugs
were used in combination which were designed to
maximize memory outcome. This response magnitude
constraint has been reported for immune stimulation, bac-
terial growth, increases in hair growth, plant growth, de-
crease in anxiety, decreases in tumor incidence and
numerous other endpoints [125].
This limitation in the magnitude of the stimulatory re-
sponse is a critical implication of the hormesis dose re-
sponse concept. It is an observation which is based on
extensive findings and it is a controlling feature which
defines what pharmaceutical companies can expect to
achieve with drugs that are designed to enhance per-
formance. However, the limitation in the magnitude of
response is also potentially important with respect to the
capacity to detect a desirable response. This may not be
a particularly important issue when using highly inbred
animal models or cell cultures where experimental con-
ditions can be highly controlled. However, attempting to
measure a low dose hormetic stimulation within the
context of a clinical trial can be problematic. Given the
likelihood of considerable human variation in response
to a drug, it is possible that the test population may have
their responsiveness distributed over a range of re-
sponses that includes toxicity, optimal response and a
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group in which the dose is ineffective. The data from all
subjects in such studies would normally be averaged to-
gether leading to a marked dilution of an overall positive
treatment effect in the optimal response zone subgroup.
This suggests a possible reason why drugs that were very
successfully tested in preclinical studies with highly in-
bred strains of animals could and often have failed
during the clinical trial. Of particular note is that investi-
gators may have to modify doses based upon the sensi-
tivity or susceptibility of the subjects. Calabrese and
Baldwin [126] have shown that the hormetic dose re-
sponse is often expressed in the broad range of subjects
independent of their susceptibility. As expected, those
individuals that are very resistant to the drug or chem-
ical treatment would have their hormetic response
shifted to the right on the dose response graph whereas
those individuals with greater than normal susceptibility
would have their hormetic response shifted to the left.
The hormetic dose response therefore imposes consider-
able challenges to the biomedical community that is in-
terested in the development of drugs that are concerned
with improvements in human performance.
The hormetic dose response can also have undesirable
effects. This may be most readily seen in the case of drugs
that are designed to suppress growth or kill cells or organ-
isms at higher doses. For example, there is now substantial
evidence that low doses of many antitumor drugs can
stimulate the proliferation of such cells at lower concen-
trations [127]. This also been shown to be the case with
antibiotics, including penicillin [128] and streptomycin
[128–130]. This phenomenon has also been reported with
selected cardiac glycosides that have effects on non-target
tissues such as the prostate where it is able to enhance the
proliferation of smooth muscle cells by about 30 % with
clinically relevant doses [130, 131]. Such a 30 % in-
crease in prostate smooth muscle was considered
likely to impede urination in males. The failure to
consider the possibility of the hormetic response not
only can lead to a lack of recognition of a desirable
drug induced response but it can also result failure to
prevent an adverse effect of drug treatment.
Of relevance to the present paper is that the hormetic
dose response has been extensively reported across the
spectrum of neuroscience research, including anxiolytic
drugs [132], anti-seizure agents [133], pain [134] mem-
ory enhancing drugs [135], brain traumatic injury [136]
several neurodegenerative diseases, including Alzheimer’s
disease and Parkinson’s disease as well as for neurite
outgrowth [137] and as astrocyte functioning [138].
Puzzo et al. [139] also reported that β-amyloid 25–35
enhanced LTP within a very detailed dose response
study, clearly demonstrating an hormetic dose response.
While numerous mechanisms have been shown to medi-
ate hormetic processes [84], one common mechanism
involved in affecting adaptive responses is the induction of
broad spectrum of stress-related proteins, such as heat
shock. The response features of these induced stress-
related proteins typically follows an hormetic like biphasic
dose response regardless of the inducing agent, affected
cell type, and endpoint. For example, methyl mercury in-
duced an hormetic biphasic dose response for GRP 78
protein expression (i.e., a marker of endoplastic reticulum
stress) in the cerebral cortex of young adult male Spra-
gue–Dawley rats [140]. The plant derived curcumin like-
wise induced a hormetic effect on proteasome activities in
human keratinocytes [141]. The widely recognized cyto-
protective heat shock protein inducing hydroxylamine de-
rivative, bimoclomol, also induced adaptive hormetic
responses in multiple systems involving a spectrum of
neuropathologies [142]. Similar hormetic patterns are very
general, extending from plants [143, 144] to invertebrates
[145–147] and to mammals [148–151] affecting multiple
indices of health and disease with a wide range of indu-
cing agents.
Heat shock also induced protection in multiple organs
including the brain with pre-conditioning protocols
[152–155]. This is of particular relevance to the present
paper because pre-conditioning represents a specific
type of hormesis with respect to study design while still
retaining its complete set of dose response features.
These collective findings demonstrate that inducers of
heat shock protein often follow an hormetic dose re-
sponse pattern, and that observed optimized protection
occurs in association with the maximal production of
the heat shock protein response [145] and that this re-
sponse can be abolished by specific pathway inhibitors,
blocking the protection, thereby providing an explana-
tory mechanism for the hormetic protective effect.
Theoretical bases and technical approaches
Redox proteomic studies
Redox proteomics is the subset of proteomics in which
oxidatively or nitrosatively modified proteins are identi-
fied, these are post-translational events that occur in the
cell resulting in post-translational modification (PTM) of
proteins.
The protein post translational modifications (PTM)
play a crucial role in modifying the end product of ex-
pression and contribute towards biological processes and
diseased conditions. Important posttranslational modifi-
cations include phosphorylation, acetylation, glycosyla-
tion, ubiquitination, and nitration [156]. The analysis of
posttranslational modifications on a proteome scale is
still considered an analytical challenge [157] because of
the extremely low abundance of modified proteins
among very complex proteome samples.
Among several types of post-translational protein modi-
fications, phosphorylation and oxidative modifications
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play essential roles in the regulation of a variety of cell
functions. Increasing evidence suggests that changes in
protein modifications over time correlate with particular
phenotypes and disease states. Reactions of free radicals
and reactive oxygen and nitrogen species (ROS and RNS)
with proteins lead to oxidative modifications such as for-
mation of protein hydroperoxides, hydroxylation of aro-
matic groups and aliphatic amino acid side chains,
nitration of aromatic amino acid residues, oxidation of
sulfhydryl groups, oxidation of methionine residues, con-
version of some amino acid residues into carbonyl groups,
cleavage of the polypeptide chain and formation of cross-
linking bonds. If oxidized proteins are not appropriately
repaired or removed from cells, they are often toxic and
can threaten cell viability [158]. Numerous studies demon-
strated the harmful effects of irreversible oxidative PTM
as a result of oxidative stress and increased levels of
oxidatively-modified proteins have been shown to correl-
ate with ageing [159]. Oxidative modifications of proteins
lead to loss of their function, enzymatic activity, accumu-
lation and inhibition of their degradation. All these meta-
bolic dysfunctions have been observed in several human
degenerative diseases such as cancer [160] and neurode-
generation [161]. Based on these findings, growing interest
is currently given to better understand selective protein
target of oxidative damage. Common markers of oxidative
stress are: protein oxidation indexed by protein carbonyls,
3-nitrotyrosine (3-NT) and protein glutathionylation
[162], lipid peroxidation indexed by thiobarbituric acid-
reactive substances (TBARS), free fatty acid release, iso-
and neuro-prostane formation, 2-propen-1-al (acrolein),
and 4-hydroxy-2-transnonenal (HNE), DNA oxidation (8-
hydroxy-2-deoxyguanosine) and advanced glycation end
products (AGE) detection. In the case of increased oxida-
tive stress, redox proteomics analyses are broadly used as
a tool to identify proteins that are modified by ROS/RNS
that contribute to the development of neurodegenerative
[163–165] and other diseases. Recently, redox proteomics
approach has been employed to identify post-translational
modification of proteins caused by oxidative damage.
Among general types of protein modifications, we focused
our attention on protein carbonyls, lipid peroxidation ad-
ducts (HNE-adducts), glutathionylation and nitration of
tyrosine residues (3-NT). An interesting bridge between
HSP and PTM and redox proteomics has been found in
the brain of subjects with AD. In the hippocampus of
these individuals, oxidation and nitration of HO-1
have been linked to loss of function in terms of neu-
roprotection secondary to the significant reduction of
BR production and BVR-ERK interaction [76]. The
lines of evidence regarding the PTM on HO-1 are re-
inforced by the concomitant findings on the PTM on
BVR’s structure [75, 166] thus corroborating the idea
of an intriguing puzzle involving HSP and proteomics.
Protein carbonylation
Carbonylation is an irreversible, non-enzymatic modifi-
cation of proteins leading to a change in their activity or
function. While protein carbonylation and the chemistry
of the reactions that give rise to carbonyl groups are
now well characterized [165], the overall biology of oxi-
dative protein modifications is a complex picture and re-
mains poorly defined. In more detail, protein
carbonylation generated by reactive carbonyl species
(RCS) arising by peroxidation of polyunsaturated fatty
acids (PUFAs) has recently gained an even greater im-
portance, in view of the emerging deleterious role of the
RCS–protein adducts in the etiology and/or progression
of several human diseases, such as cardiovascular (ath-
erosclerosis, long-term complications of diabetes) and
neurodegenerative diseases (AD, PD and cerebral ische-
mia). Most of the biological effects of intermediate RCS
are due to their capacity to react with the nucleophilic
sites of proteins, binding to the sulfhydryl group of cyst-
eine (Cys), the ε-amino group of lysine (Lys) or the imid-
azole group of histidine (His) residues to form Michael
or Schiff base protein adducts, known as advanced
lipoxidation end-products (ALEs) [167]. As a conse-
quence, determination of the biochemical factors that
induce cellular responses resulting from protein car-
bonylation is now considered a key element to devel-
oping therapeutic approaches and ameliorating disease
pathologies [168].
Indeed, proteins can be modified through the reac-
tion between arginine and lysine amino groups with
reducing sugars or reactive aldehydes, such as glyoxal
and methylglyoxal, based on the Maillard reaction.
This reaction is named glycation or non-enzymatic
glycosylation. Glycation, which leads to the formation
of early stage glycation adducts and then advanced
glycation end products (AGE), is considered as one of
the major cause of spontaneous damage to cellular
and extracellular proteins [169]. Formation of AGEs
on proteins is found in many tissues and is thought
to contribute to a variety of age-associated diseases,
such as AD and PD [170]. Although glycation is not
an oxidative phenomenon, it can be amplified by oxi-
dative stress and hence referred as to glycoxidation
[171]. Thus, under conditions of oxidative stress, re-
ducing sugars (glucose, fructose) and ascorbic acid
can be self-oxidizing generating highly reactive dicar-
bonyl compounds, which can in turn react with pro-
teins to form AGEs. Finally, among the most
important glycating agents are the dicarbonyl com-
pounds glyoxal and methylglyoxal that are derived
from glucose auto-oxidation and glycolytic intermedi-
ates. The reactivity of these dicarbonyls is much
higher than that of glucose, so they represent import-
ant precursors of AGEs in physiological systems.
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Interestingly, carbonylated adducts are being formed
upon conjugation with these by dicarbonyl com-
pounds. In addition, ROS can oxidize membrane
lipids generating lipid hydroperoxides and many alde-
hydes such as acrolein, malonaldehyde, 4-hydroxy-2-
nonenal (HNE) and other hydroxyalkenals.
Lipid peroxidation adducts (HNE-adducts)
Lipid peroxidation is one of the major sources of free
radical mediated injury that directly damages mem-
branes and generates a number of secondary products.
The overall process of lipid peroxidation consists of
three stages: initiation, propagation and termination.
Free-radical-mediated lipid peroxidation, occurs when a
carbon-centred radical is produced on a PUFA (polyun-
saturated fatty acid) by the abstraction of an allylic
hydrogen by some form of radical present within the bi-
layer, for example the sulfuranyl free radical on Met35
ofAβ-(1– 42). Oxygen, which lacks a dipole moment,
diffuses into the lipid bilayer where it may react with the
carbon-centred radical to form a lipid peroxyl-radical
[172, 173]. The lipid peroxyl-radical may then abstract
an allylic hydrogen from an adjacent polyunsaturated
lipid which propagates the chain reaction and forms a
lipid hydroperoxide that may then undergo cleavage
forming an array of possible reactive aldehydes such as
F2-isoprostane, HNE and 2-propenal (acrolein). HNE for
example is primarily produced from arachidonic acid, an
omega-6 PUFA with inflammatory and signalling proper-
ties of its own. In neuronal cells under Aβ toxicity an in-
crease in HNE to concentrations of 5–10 μM was
demonstrated within the lipid bilayer [174]. HNE and
malondialdehyde (MDA) are significantly elevated in
several neurodegenerative diseases [175, 176]. HNE can
accumulate in cells in relatively high concentrations and
cause cell toxicity. Increased levels of HNE cause disrup-
tion of Ca2þ homeostasis, glutamate transport impair-
ment, membrane damage, and cell death [177]. Once
formed, HNE can covalently modify cysteine, lysine, or
histidine residues by Michael addition altering protein
structure and causing loss of function and activity [178].
Several methods have been developed for detection of
free HNE, its metabolites, or its conjugation products
with biomolecules. Other PUFAs that are important in
the generation of lipid peroxidation products are LA
(linoleic acid), DHA (docosohexanoic acid) and choles-
terol, among others [173].
Glutathionylation
One of the most common outcomes of a rise in
cellular oxidant levels is the modification of redox-
sensitive proteins via a process known as S-
glutathionylation [179]. Glutathionylation occurs as a
posttranslational modification of proteins at the
cysteine residues by adding a glutathione (GSH, γ-
glutamylcysteinylglycine) moiety [180]. Glutathione is
a ubiquitous tripeptide that acts as an inherent anti-
oxidant, and works in conjunction with oxidised
glutathione (glutathione disulphide, GSSG) as an
intracellular redox buffer. Glutathionylation can pro-
tect cysteine thiols against irreversible oxidation but
can also alter, either positively or negatively, the activ-
ity of many proteins. Therefore, glutathionylation al-
lows cells to sense and signal harmful stress
conditions and trigger appropriate responses [181].
Protein disulfides are formed by the action of protein
disulfide isomerase in the endoplasmic reticulum
(ER). Inappropriate disulfide bridges (and cysteine sul-
fenic acids) arise in response to OS and are under
the reversible control of the thioredoxin reductase
system. Oxidatively damaged proteins have been re-
ported as being cleared via ubiquitinylation followed
by digestion in the 20S core of the 26S proteasome
in the cytosol and nucleus [182]. Thus targeting
ubiquitin bound to protein can be used as a param-
eter of protein oxidation. However, protein oxidation
and ubiquitinylation might not be always directly
correlated [183].
To date, a number of proteins have been identified
that undergo S-glutathionylation, often in response to
oxidative stress. S-Glutathionylation of proteins can in-
duce a range of consequences [184], including a down-
regulation [185, 186] or upregulation [187] of enzymatic
activity, altered DNA binding by transcription factors
[188, 189], and increased [190] or decreased [191]
protein stability.
Nitration of tyrosine residues (3-NT)
3-NT (3-nitrotyrosine), a PTM of tyrosine, is a well-
recognized marker of nitrosative stress. The formation
of 3-NT is the product of the reaction between ONOO−
and CO2 which form both NO2, a free radical, and the
carbonate radical (CO3• −) through the intermediates
nitrosoperoxycarbonate and nitrocarbonate [192]. How-
ever, there is evidence for alternative pathways, including
one mediated by myeloperoxidase [193]. Nitration of
tyrosine may also result in stearic hindrance that blocks
a potential phosphorylation at the 4- paraposition, af-
fecting the potential of tyrosine to be phosphorylated,
resulting in a potential for decreased tyrosine signalling
[152]. A decrease in tyrosine signalling may result in the
progression of neurodegenerative diseases and increased
3-NT levels have been detected in AD, ALS, PD, athero-
sclerosis, and acute lung disease disorders [193, 194]. 3-
NT formation has recently been linked to systemic
autoimmune disorders such as lupus through the gener-
ation of endogenous antibodies against native proteins
that may be nitrated [192].
Dattilo et al. Immunity & Ageing  (2015) 12:20 Page 11 of 19
Redox proteomics methods
The complexity of tissue and body fluid proteomes calls
for a separation step ahead of mass spectrometric (MS)
analysis. Depending on the composition of the prote-
ome, several well studied separation techniques are
available including two-dimensional gel electrophoresis
(2D-DE), liquid chromatography (LC) and capillary elec-
trophoresis (CE) that are used in redox proteomics re-
search into two major approaches; gel-based and non
gel-based methods. With respect to the separation and
mass spectrometric technique selected, proteins may
have to be fractionated in a controlled manner into pep-
tides through enzymatic digestion using e.g., trypsin up
or downstream of the separation step.
Gel–based methods
In gel-based methods, oxidized proteins extracted from
biological tissues are separated using for example two-
dimensional polyacrylamide gel electrophoresis (2-D
PAGE) [195]. 2-D PAGE is currently one of the powerful
protein separation method for the resolution of complex
mixtures of proteins, permitting the simultaneous ana-
lysis of thousands of gene products. Proteins are sepa-
rated according to their charge (pI) by isoelectric
focusing (IEF) in the first dimension and according to
their size (Mr) by SDS-PAGE in the second dimension.
The introduction of immobilized pH gradients (IPG) for
IEF has overcome the problems of pH gradient instabil-
ity (caused by prolonged focusing time). IPGs allow the
generation of pH gradients of any desired range (broad,
narrow or ultra-narrow) between pH 3 and 12. In
addition, the use of pH gradient allowed high riproduci-
bility and large scale separations. However some limita-
tions still remain to be solved including solubilization of
membrane proteins, identification of low-abundance
proteins and identification of highly idrofobic proteins.
Coupled 2D-PAGE with immunochemical detection of
protein carbonyl derivatized by 2,4-dinitrophenyhydra-
zine (DNPH), nitrated proteins indexed by 3-
nitrotyrosine (3-NT), glyutathionylated proteins (GSH-
bound proteins) and HNE-bound proteins followed by
MS analysis is a workflow utilized in redox proteomics.
Western blotting (WB) is usually incorporated in 2D-gel
based redox proteomics because immunochemical de-
tection of oxidatively modified proteins offers high sensi-
tivity and specificity. A 2D western blot map is achieved
by using specific antibodies, e.g., anti-DNP, anti-3-NT,
anti-GSH or anti-HNE, that react with those proteins
containing reactive carbonyl groups/3-NT/GSH/HNE.
2D gel images, used to obtain the protein expression
profile, and the 2D western blots are analyzed by image
software (PD Quest, BioRad). This sophisticated software
offers powerful comparative analysis and is specifically
designed to analyze many gels or blots at once that were
performed under identical experimental conditions.
Powerful automatching algorithms quickly and accur-
ately match gels or blots and sophisticated statistical
analysis tools identify experimentally significant spots.
The principles of measuring intensity values by 2D ana-
lysis software are similar to those of densitometric mea-
surements. After completion of spot matching, the
normalized intensity of each protein spot from individ-
ual gels (or membranes) is compared between groups
using statistical analysis [196].
Oxidized spots of interest are excised from the gel and
identified using a peptide mass fingerprinting (PMF) MS
approach [164, 197–199] The PMF approach can be car-
ried out with matrix-assisted laser desorption ionization
(MALDI)-MS or electrospray ionization (ESI)-MS. Gel-
based methods are advantageous because they target a
specific subset of the proteome and numerous gels can
be ran and aligned with sophisticated software tools. An-
other used gel based redox proteomics method is two-
dimensional difference gel electrophoresis (2D-DIGE).
This method uses fluorescent dyes (e.g., Cy2, Cy3, and
Cy5) to covalently label protein samples, allowing two to
three samples to be analyzed simultaneously on the
same gel in which signals are scanned at different wave-
lengths [200]. The common labeled residues are cysteine
and lysine with functional NHS-ester and maleimides
dyes, respectively. Incorporation of multiple dye mole-
cules into protein sequence may change its migration
significantly therefore minimal labeling has been devel-
oped to address this issue [201]. 2D-DIGE technique
addresses the limitations of lack of reproducibility
between gels and has femptomolar sensitivity and a
104dynamic range [202].
Non Gel-based methods
A non gel based proteomic method includes the diges-
tion of proteins into peptides in solution, the nanoflow
liquid chromatography (LC) separation or capillary elec-
trophoresis (CE) of peptides and automated MS and
MS/MS data acquisition. LC comprises high perform-
ance liquid chromatography (HPLC) or ultra high
performance liquid chromatography (UHPLC) to achieve
a high-resolution separation of various chemically differ-
ent compounds depending on the LC column. Separ-
ation is achieved via differences in the affinities/
distribution between the stationary and mobile phase.
Modern nano LC systems achieve high resolution separ-
ation of peptides and are excellent tools for shot gun
proteomics combined with data-dependent analysis
[203]. Multi-dimensional protein identification technol-
ogy (MudPIT) based on2-D LC allows the analysis of
highly complex samples (tissues and body fluids) [204].
The high sensitivity associated with LC can also become
a limitation towards interfering compounds. Sample
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carry-over is another limitation of LC characterised by
the detection of residual analytes from previous mea-
surements introducing biases into newer analyses [205].
Capillary electrophoresis perform separation of analytes
from a complex protein mixture in a single step and
with high resolution through buffer-filled capillaries
flowing in a strong electrical field (300–500 V/cm).
Additionally, CE–MS is fast, enabling separation of sev-
eral thousand peptides in 60 min in a single run making
it an ideal technology to be used in clinical proteomics
[206]. A potential limitation is the fact that only small
sample volumes can be applied to CE capillaries even if
stacking approaches are used. In addition, the technique
is not appropriate for the separation of proteins >20 kDa
due to potential precipitation. With recent developments
in mass spectrometry, such as isobaric tags for relative
and absolute quantitation (iTRAQ) (Unwin et al.) se-
lected reaction monitoring (SRM, which is also termed
multiple reaction monitoring or MRM, [207], as well as
stable isotope standards and capture by anti-peptide
antibodies, the non-gel proteomic approach has become
the method of choice because of its efficiency and con-
venience. Compared to the traditional gel-based method
which is more complicated, the non-gel proteomic ap-
proach requiresonly 3 steps: digestionand labeling of re-
sultant peptides, the separation of peptides and
automated data acquisition.
Below, we report key examples of these recently re-
ported non-gel proteomic approaches which hold the
potential for identification of novel redox regulations as-
sociated with different disease. To quantify the level of
the thiol modifications under oxidative stress conditions,
thiol trapping techniques and isotope coded affinity tag
(ICAT) can be combined to label unmodified and oxi-
dized thiol groups with light and heavy tags, respectively
[208]. This method named NOxICAT is specific for
nitrosative and oxidative modifications of thiol groups.
After protein denaturation, free thiol groups are labeled
with light ICAT reagents. Oxidized thiols are labeled
with heavy ICAT reagents and the extent of cysteine oxi-
dation is measured by quantifying the relative ratios of
light and heavy labeled peptides with MS. The Tandem
Mass Tag(TMT) approach, which enables concurrent
identification and multiplexed quantitation of proteins
in different samples, is a well-established multiplex mass
spectrometry analysis method. CysTMT is a version of
the TMT approach that is thiol reactive [209]. The
cysTMT reagents, which are several isobaric (mass and
structure) isomers, can be used to label the sulfhydryl
(−SH) groups irreversibly. CysTMT reagents react spe-
cifically with reduced cysteines in peptides and proteins.
After labeling, peptides with various cysteine modifica-
tions, such as oxidation, disulfide bonds and S-
nitrosylation can be identified and quantified by MS.
Compared with the traditional biotin switch technique
that has been widely used for identification of protein S-
nitrosylation [210], this new reagent fulfills the require-
ments for a biotin switch label and offers some distinct
advantages, including a permanent mass tag and the
fragmentation of up to 6 isotopically balanced reporter
ions between 126 and 131 Da permitting multiplex
quantification [211]. Non-gel redox proteomics have
been widely applied in the study of protein carbonyla-
tion. A key step in these approaches is the incorporation
of enrichment procedures for protein carbonyl (PCO)
which is necessary since the average abundance of car-
bonylated proteins has been reported as 0.2 % in human
plasma [212]. Some reagents are able to directly increase
the ionization efficiency of PCO prior to MS analysis.
An example is dansylhydrazide which enhances effi-
ciency of ionization due to its secondary nitrogens. Dan-
sylhydrazide generates reproducible fragmentation
patterns which allows MS3 scans to be employed for
localization of PCO sites in proteins [213].
Conclusions and perspectives
Although continually increasing resources are being
expended to combat age-related diseases such as AD,
PD, diabetes, osteoporosis, metabolic syndrome, and
cancer, yet, the causal identification of these disease re-
main elusive. Thus, incidence and morbidity remain ei-
ther constant or increase. Huge investments in
biomedical research in the recent past have resulted in
some striking accomplishments, including the sequen-
cing of the human chromosomal single nucleotide poly-
morphisms (SNPs), and the identification of regional
clusters of chromosomal SNPs (the HapMap). How-
ever, these accomplishments have failed to reveal the
anticipated genetic causes for the common age-related
diseases [214].
Modulation of endogenous cellular defense mecha-
nisms via the stress response signaling represents an in-
novative approach to therapeutic intervention in
diseases causing tissue damage, such as neurodegenera-
tion, for example is reported how drugs that modulate
proteostasis by inhibiting Hsp90 function or promoting
Hsp70 function enhance the degradation of the critical
aggregating proteins and ameliorate toxic symptoms in
cell and animal disease models [215]. Efficient function-
ing of maintenance and repair processes seems to be
crucial for both survival and physical quality of life. This
is accomplished by a complex network of the so-called
longevity assurance processes, which are composed of
several genes termed vitagenes. Consistently, by main-
taining or recovering the activity of vitagenes can be
possible to delay the aging process and decrease the oc-
currence of age-related diseases with resulting prolonga-
tion of a healthy life span [2, 69, 216–218] As one of the
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most important neurodegenerative disorders, AD is a
progressive disorder with cognitive and memory decline,
speech loss, personality changes and synapse loss. With
the increasingly aging population of the United States,
the number of AD patients is predicted to reach 14 mil-
lion in the mid-21st century in the absence of effective
interventions. This will pose an immense economic and
personal burden on the people of this country. There is
now strong evidence to suggest that factors such as oxi-
dative stress and disturbed protein metabolism and their
interaction in a vicious cycle are central to AD patho-
genesis. Brain-accessible antioxidants, potentially, may
provide the means of implementing this therapeutic
strategy of delaying the onset of AD, and more in gen-
eral all degenerative diseases associated with oxidative
stress. As one potentially successful approach, potenti-
ation of endogenous secondary antioxidants systems can
be achieved by interventions which target the HO-1/CO
and/or Hsp70 systems.
The hormetic dose–response, challenges long-standing
beliefs about the nature of the dose–response in a low-
dose zone, having the potential to affect significantly the
design of pre-clinical studies and clinical trials as well as
strategies for optimal patient dosing in the treatment of
numerous diseases [219, 220]. Reports exist of enhanced
longevity via treatment with a large number of agents in
a wide range of animal models displaying hormetic dose
responses [25]. The generality of the hormetic dose re-
sponse, being independent of biological model, endpoint,
inducing agent and mechanism and with its quantitative
features being a measure of plasticity constrained bio-
logical performance, strongly suggests that attempts to
extend normal lifespan will be likewise limited to the
30–60 % as has been typically reported. Thus, hormesis
has a fundamental role in aging research, affecting both
the quality and the length of life as well as affecting the
research methods (e.g., study design, statistical power,
etc.) by which such biological concepts are studied.
Consisent to this notion, Protein redox regulation
plays important roles in many biological processes. Pro-
tein cysteine thiols are sensitive to redox changes and
may function as redox switches, which turn on or turn
off signaling and metabolic pathways to ensure speedy
responses to environmental stimuli or stresses. Novel in-
tegrative proteomics methods combining different iso-
baric tags in one experiment will permit simultaneous
analysis of cysteine redox changes and total protein level
changes, also allowing determination of redox modifica-
tion in the cysteine pool in proteins. Thus, the capability
to analyze protein posttranslational modification
dynamics and protein level changes, particularly
exploiting cellular stress proteome in one experiment
will advance proteomic studies in many fields of
biology and medicine.
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